On April 23, 2026, Acting Attorney General Todd Blanche signed an order moving both FDA-approved marijuana products and state-licensed medical marijuana from Schedule I to Schedule III of the Controlled Substances Act, following a December 2025 executive order (EO 14370) directing the Attorney General to expedite this process. This is a genuinely significant regulatory change, but it's important to be precise about what it does and doesn't do: it does not legalize recreational marijuana, and it does not legalize possession outside the specific categories covered (FDA-approved products and state-licensed medical marijuana).
A separate, expedited administrative hearing process began June 29, 2026, to consider the broader question of rescheduling all marijuana, not just the medical categories already addressed. As of this writing, that broader rescheduling process remains ongoing and unresolved. Legal experts note that full federal legalization would require an actual act of Congress, since rescheduling under the Controlled Substances Act, even completed, is a different and narrower legal action than legalization.
California became the first state to legalize medical marijuana in 1996. As of March 2026, 40-41 states (sources vary slightly by exact count and territory inclusion), plus D.C., Puerto Rico, Guam, and the U.S. Virgin Islands, have comprehensive medical marijuana laws, according to Congressional Research Service tracking. Nearly half of all states have gone further and enacted adult-use (recreational) legalization for adults specifically.
This created what CRS explicitly describes as a "policy gap": these state laws technically remain in violation of federal law, since federal marijuana policy hadn't meaningfully changed in decades, even as the large majority of states adopted some form of legal access. The April 2026 rescheduling action doesn't fully close this gap, but does reduce it for the specific medical marijuana category.
Marijuana Moment's reporting describes 2026 as holding "both great potential and great peril" for state cannabis policy specifically because, for the first time, ballot initiatives may qualify in some states to actually reinstate marijuana prohibition, running counter to the two-decade trend of expanding legalization. At the same time, two large states, one generally politically purple and one generally red, are described as potentially moving toward legalizing cannabis for adults in 2026, and advocates suggest federal rescheduling itself could provide momentum for reform in states that have so far resisted any legalization.
Legalization advocates generally argue that decades of state-level experience show regulated legal markets reduce illicit sales and generate tax revenue without the predicted surge in serious social harms, and that continued federal prohibition creates unnecessary legal risk and research barriers. Opponents of further legalization generally cite concerns about youth access, impaired driving, and the relatively limited long-term research on regular use, particularly for developing brains, a concern that current rescheduling is specifically expected to help address by easing research restrictions rather than resolve immediately. Both sides broadly acknowledge the federal-state policy gap itself, decades of state laws technically violating unchanged federal law, was an unsustainable, confusing status quo regardless of one's underlying view on legalization; the actual disagreement is over which direction that gap should be closed.
Want the core arguments from both sides, side by side?
See the Left vs. Right Breakdown on Marijuana Legalization →